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Background: Colorectal cancer (CRC), a heterogeneous disease that is common in both men and women, con-
tinues to be one of the predominant cancers worldwide. Lifestyle, diet, environmental factors and gene defects
all contribute towards CRC development risk. Therefore, the identification of novel biomarkers to aid in theman-
agement of CRC is crucial. The aim of the present study was to identify candidate biomarkers for CRC, and to de-
velop a better understanding of their role in tumourogenesis.
Methods: In this study, both plasma and tissue samples from patients diagnosed with CRC, together with non-
malignant and normal controls were examined using mass spectrometry based proteomics and metabolomics
approaches.
Results: It was established that the level of several biomolecules, including serotonin, gamma enolase, pyruvate
kinase and members of the 14-3-3 family of proteins, showed statistically significant changes when comparing
malignant versus non-malignant patient samples, with a distinct pattern emerging mirroring cancer cell energy
production.
Conclusion: The diagnosis and management of CRC could be enhanced by the discovery and validation of new
candidate biomarkers, as found in this study, aimed at facilitating early detection and/or patient stratification to-
gether with providing information on the complex behaviour of cancer cells.© 2015 Elsevier B.V. All rights reserved.1. Introduction
Colorectal cancer (CRC) is the secondmost common cause of cancer-
related death worldwide and places an enormous cost to society in
direct healthcare expenditures. Globally, CRC is the third most com-
monly diagnosed cancer in males and the second in females, with over
1.2 million new cases and 608,700 deaths estimated to have occurred
in 2008 [1]. The highest incidence rates of CRC are in Oceania, Europeassay;HPLC, High-performance
ry;m/z, mass-to-charge ratio.
ational University of Ireland,
086368; fax: +353 1 7083845.and North America, whereas the lowest rates are found in Africa,
South-Central Asia and Latin America [1,2]. More than 90% of colorectal
carcinomas are adenocarcinomas originating from epithelial cells of the
colorectal mucosa. Other types of cancer that can occur here include
neuroendocrine, squamous cell, adenosquamous, spindle cell and undif-
ferentiated carcinomas [3]. In most people, CRC develops slowly over a
period of typically a few decades, presenting an opportunity for early
detection and intervention to improve patient outcomes [4]. In this re-
gard, biomarkers can potentially be used clinically to aid early detection,
diagnosis and disease monitoring or to guide therapy selection for CRC
patients.
The discipline of proteomics is an importantmeans to help solve the
complex physiological and biochemical mechanisms/pathways with
the ultimate goal of identifying new opportunities for developing new
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most readily accessible clinical sample for the investigation of bio-
markers. The fact that the serumand plasmaproteomes have a large dy-
namic range in protein concentration, perhaps as high as 15 orders of
magnitude, hampers the development of clinical biomarkers [6,7]. A
range of fractionation techniques are available to facilitate researchers
to this end, including traditional chromatography [8], immunodepletion
[9], nanoparticle enrichment [10] and ProteoMiner™ technology [11],
which has been used in this investigation.
State-of-the-art technologies for metabolomics analysis, has
sparked renewed interest in this important research area, and this
may complement proteomic analysis [12]. Identifying, quantifying and
understanding variations in the concentration of various metabolites,
in combination with proteomics screening, is a powerful strategy for
understanding the complex mechanisms in such biological systems.
This study combines proteomic and metabolomic approaches to
identify circulating biomolecules that discriminate malignant from
non-malignant (polyps, adenomas) patients. Differential protein and
metabolite expression analysis, by measuring upregulated or downreg-
ulated biomolecules in CRC,may contribute to a better understanding of
disease mechanisms and could provide clinicians with a suite of bio-
markers to complement existing strategies for the management of
CRC patients. Interestingly, the data presented in this study on a series
of proteins andmetabolites, identified a noticeable link to changes asso-
ciated with the characteristic metabolic profile of most tumour cells
[13].
2. Materials and methods
2.1. Patient selection and sample collection
Cases with positive colonoscopy results for malignancy, confirmed
by histology as colon or rectal carcinomas, were recruited between
December 2007 andDecember 2010 at theDepartments of Gastroenter-
ology and Surgery, Adelaide and Meath Hospital, Dublin, Ireland and at
the Thomayer Teaching Hospital in Prague, Czech Republic. Control
subjects or subjects diagnosed with polyps or adenomatous polyps
were acquired during the same period from individuals undergoing co-
lonoscopy for various gastrointestinal complaints (macroscopic bleed-
ing, positive faecal occult blood test or abdominal pain of unknown
origin). The participating subjects gave written informed consent in
accordance with the Declaration of Helsinki at the participating site
thatwas approved by local ethics committees. See Table 1 for clinical in-
formation on samples used. The samples were collected according to
standard phlebotomy procedures from consented patients. A total of
10ml of blood was collected into an EDTA plasma tube and centrifuged
at 1000×g for 30min at 4 °C. Plasmawas aliquoted in the cryovial tubes,
labeled and stored at −80 °C until time of analysis. The time fromTable 1
Patient data table.
n (M/F) Average age
Discovery set
Control 10 (5/5) 67 ± 11
CRC Stage III 8 (4/4) 57 ± 9
CRC Stage IV 8 (4/4) 60 ± 5
Validation set
Control 20 (12/8) 63 ± 8
Polyps 10 (6/4) 58 ± 8
Adenoma 10 (6/4) 61 ± 11
CRC Stage I 10 (5/5) 62 ± 9
CRC Stage II 10 (5/5) 60 ± 14
CRC Stage III 10 (5/5) 67 ± 11
CRC Stage IV 10 (5/5) 63 ± 12
Clinical information on the discovery and validation plasma sample cohorts. M denotes
male; F denotes female.sample procurement to storage at−80 °C was less than 3 h. Each plas-
ma sample underwent not more than three freeze/thaw cycles prior to
analysis.
2.2. Metabolomics analysis
Plasma specimens (250 μl) were shipped on dry ice to Metabolon
Inc., Durham, North Carolina, USA, where the metabolomic profiling
was performed. Metabolon incorporates three independent compli-
mentary analysis platforms tomaximise the number of small molecules
and metabolites that the combined systems can identify and measure.
Two independent ultra-high performance liquid chromatography/
tandemmass spectrometry (UHPLC/MS/MS2) injections (one optimised
for basic compounds and the other for acidic compounds) and one Gas
chromatography–mass spectrometry (GC/MS) injection per sample are
performed. Firstly, small molecules were extracted from plasma speci-
mens using methanol to allow precipitation of proteins. The extract su-
pernatant was then split into four equal aliquots; two for UHPLC/MS,
one for GC/MS and one reserve aliquot. Aliquots were then dried over-
night to remove solvent.
For the UHPLC methods, one aliquot was reconstituted in 50 μl 0.1%
formic acid and the other in 50 μl 6.5 mM ammonium bicarbonate
pH 8.0. For GC/MS analysis, aliquots were prepared using equal parts
N,O-bistrimethylsilyltrifluoroacetamide and a solvent mixture of
acetonitrile/dichloromethane/cyclohexane (5:4:1)with 5% triethylamine
at 60 °C for 1 h. All reconstitution solvents contained instrument internal
standards used to monitor instrument performance [14,15].
UHPLC/MSwas carried out using aWaters Acquity UHPLC coupled to
an LTQ mass spectrometer equipped with an electrospray ionization
source. Two independent UHPLC/MS injections were performed on
each sample. The acidic injections were monitored for positive ions
and the basic injections were monitored for negative ions. The
derivatised samples for GC/MS were analyzed on a Thermo-Finnigan
Trace DSQ fast-scanning single-quadrupole MS. The resulting MS/MS2
datawere then searched againstMetabolon's reference standard library.
This library was generated from 1500 standards and contains the
retention time/index, mass to charge (m/z), and MS/MS spectral data
for all molecules in the library, including their associated adducts,
in-source fragments, and multimers. The library allows identification
of experimentally detected metabolites based on a multi-parameter
match basis. All identifications and quantifications were subjected to
quality control (QC) to verify the quality of the identification and peak
integration.
2.3. ProteoMiner™ fractionation
Plasma protein equalization was performed using ProteoMiner™
enrichment kit according to the manufacturer procedure (Bio-Rad
Laboratories, CA, USA). In summary, the storage solution was first
washed out from the spin column containing 100 μl of peptide beads
with deionised water. Thereafter, the column was washed with the
10 mM NaH2PO4, 150 mM NaCl, pH 7.4 solution provided with the kit.
When the spin column was ready for sample binding, 1 ml of centri-
fuged plasma sample was added to the column and equilibrated at
room temperature for 2 h. The unbound proteins were removed with
the wash buffer and the captured proteins were eluted by 3 × 100 μl
of 8 M urea containing 2% CHAPS dissolved in 5% acetic acid.
Following vortexing, sonication and centrifugation, the protein
concentration of control and stage III/IV CRC patient samples was deter-
mined. Volumes of protein suspensions were equalised using label-free
solubilisation buffer and then reduced for 30 min with 10 mM dithio-
threitol (DTT) and alkylated for 20 min in the dark with 25 mM
iodoacetamide in 50 mM ammonium bicarbonate. The proteolytic di-
gestion of proteins was carried out in two steps. Firstly, digestion was
performed with sequencing grade Lys-C at a ratio of 1:100 (protease/
protein) for 4 h at 37 °C, followed by dilution with four times the initial
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digestion was based on incubation with sequencing grade trypsin at a
ratio of 1:25 (protease/protein) overnight at 37 °C. The protease-
treated plasma protein suspensions were diluted 3:1 (v/v) with 2%
trifluoroacetic acid in 20% acetonitrile. To ensure an even suspension
of peptide populations from control and stage III/IV CRC patient
samples, the samples were briefly vortexed and sonicated.
2.4. Label-free LC-MS/MS analysis
The nano LC-MS/MS analysis of control versus stage III/IV CRC pa-
tient samples was performed using an Ultimate 3000 nanoLC system
(Dionex (UK) Ltd., Camberley, Surrey, UK) coupled to a an LTQ Orbitrap
XLmass spectrometrer (Thermo Fisher Scientific, Dublin, Ireland) in the
Proteomics Facility of the National Institute for Cellular Biotechnology,
Dublin City University. The optimised methodology has been as previ-
ously described in detail [16]. Peptidemixtures (5 μl volume)were load-
ed onto a C18 trap column (C18 PepMap, 300 μm id × 5 mm, 5 μm
particle size, 100 Å pore size; Dionex). Desalting was achieved at a
flow rate of 25 μl/min in 0.1% TFA for 10 min. The trap column was
switched on-line with an analytical PepMap C18 column (75 μm
id × 500mm, 3 μmparticle and 100 Å pore size; Dionex). Peptides gen-
erated from plasma proteinswere elutedwith the following binary gra-
dients: solvent A (2% ACN and 0.1% formic acid in LC-MS grade water)
and 0–25% solvent B (80% ACN and 0.08% formic acid in LC-MS grade
water) for 240 min and 25–50% solvent B for a further 60 min. The col-
umn flow rate was set to 350 nl/min. Data were acquired with Xcalibur
software, version 2.0.7 (Thermo Fisher Scientific). The MS apparatus
was operated in data-dependent mode and externally calibrated. Sur-
vey MS scans were acquired in the Orbitrap in the 300–2000 m/z
range with the resolution set to a value of 30,000 at m/z 400 and lock
mass set to 445.120025 u. CID fragmentation was carried out in the lin-
ear ion trapwith the threemost intense ions per scan.Within 60 s, a dy-
namic exclusion window was applied. Normalised collision energy of
35%, an isolation window of 3m/z and onemicroscan were used to col-
lect suitable tandem mass spectra.
2.5. Quantitative profiling by label-free LC-MS/MS analysis
Processing of the raw data generated from LC-MS/MS analysis was
carried out with Progenesis label-free LC-MS software (version 3.1;
Non-Linear Dynamics, Newcastle upon Tyne, UK). Data alignment was
based on the LC retention time of each sample, allowing for any drift
in retention time given an adjusted retention time for all runs in the
analysis [16]. A reference run was established with the sample run
that yielded most features (i.e. peptide ions). The retention times of all
of the other runswere aligned to this reference run and peak intensities
were then normalised. Prior to exporting the MS/MS output files to
MASCOT (www.matrixscience.com) for protein identification, a num-
ber of criteria were employed to filter the data including: (i) peptide
features with ANOVA b 0.05 between experimental groups, (ii) mass
peaks (features) with charge states from +2, +3, and (iii) greater
than one isotope per peptide. A MASCOT generic file was generated
from all exported MS/MS spectra from Progenesis software. The
MASCOT generic file was used for peptide identification with MASCOT
(version 2.2) and searched against the UniProtKB-SwissProt database
(downloaded in January 2013) with 16,638 proteins (taxonomy:
Homo sapiens). The following search parameters were used for protein
identification: (i) MS/MS mass tolerance set at 0.5 Da, (ii) peptide
mass tolerance set to 20 ppm, (iii) carbamidomethylation set as a
fixed modification, (iv) up to two missed cleavages were allowed and
(v)methionine oxidation set as a variablemodification. For further con-
sideration and re-importation back into Progenesis LC-MS software for
further analysis, only peptides with ion scores of 40 and above were
chosen. Importantly, the following criteriawere applied to assign a plas-
ma associated protein as properly identified: (i) an ANOVA scorebetween experimental groups of ≤0.05, (ii) proteins with ≥1 peptides
matched and (iii) a MASCOT score N40.
2.6. Enzyme-linked immunosorbent assay
Plasma samples were screened using different enzyme-linked
immunosorbent assays for 14-3-3, NSE (gamma enolase), M2-PK and
Serotonin. Serotonin levels were analysed using a colorimetric competi-
tive enzyme immunoassay with absorbances read at 405 nm (Enzo Life
Sciences, Farmingdale, NY, USA: ADI-900-175). NSE and the 14-3-3 fam-
ily of proteinswere assayed using the quantitative sandwich enzyme im-
munoassay technique (CSB-E07961h and CSB-E12010h Cusabio Biotech,
Wuhan, China). M2-PK levels were analysed using the ScheBo® • Tumor
M2-PK™ EDTA Plasma Test (ScheBo Biotech AG, Giessen, Germany).
2.7. Immunohistochemistry
A commercially available colon cancer Tissue Microarray (TMA),
(AccuMax A713(VII), ISU/ABXIS Co., Seoul, Korea) comprising 24 cores
of colon cancer tissues with corresponding normal tissues was stained
for 14-3-3 ε expression using an anti-14-3-3 ε polyclonal antibody suit-
able for Immunohistochemistry (IHC) (NBP1-89827; Novus Biologicals
Littleton, CO, USA). Staining was performed using an automated stain-
ing apparatus for IHC (Autostainer, Dako, Glostrup, Denmark) according
to the manufacturer's guidelines. Briefly following de-paraffinisation
and rehydration, the slides were subjected to an antigen retrieval step
consisting of 20-min incubation in pH 6.0 buffer (Target Retrieval,
Dako, Glostrup, Denmark). The slides were counterstained with
haematoxylin, dehydrated in graded alcohols and glass-mounted
(DPX, Sigma). Negative control (primary antibody omitted, replaced
by TBS) and positive control (tonsil) slides were processed at the
same time. TMA cores were scored according to the intensity of the
14-3-3 ε immunoreactivity observed (categorised as weak, moderate,
or strong).
2.8. Statistical analysis
The Mann–Whitney U Test (Wilcoxon Rank-Sum Test) was used to
determine the p-values for specific proteins between control, polyps,
adenoma and stages I-IV CRC patient plasma samples. ELISA data were
analysed by constructing a standard curve as a result of plotting the
mean absorbance for each standard on the x-axis against the concentra-
tion on the y-axis and drawing a best fit curve through the points on the
graph. Receiver-operating characteristic (ROC) curve analysis was per-
formed as it is a useful tool in assessment of biomarker accuracy. The
ROC plots were obtained by plotting all sensitivity values (true positive
fraction) on the y-axis against their equivalent (1-specificity) values
(false positive fraction) for all available thresholds on the x-axis
(MedCalc, version 13-0-0-0 64-bit, Medcalc Software, Mariakerke,
Belgium). The area under the curve (AUC) was calculated to provide a
summary of overall classifier effectiveness.
3. Results
3.1. Patient data
The discovery set of samples included controls = 10, (5/5), 67 ± 11
(number, (male/female), average age ± standard deviation), CRC
Stage III = 8 (4/4), 57 ± 9 and CRC Stage IV = 8 (4/4), 60± 5. The val-
idation set of samples included controls = 20 (12/8), 63 ± 8, Polyps =
10 (6/4), 58±8, Adenomas=10 (6/4), 61±11, CRC Stage I=10 (5/5),
62± 9, CRC Stage II = 10 (5/5), 60± 14, CRC Stage III = 10 (5/5), 67±
11 and CRC Stage IV = 10 (5/5), 63 ± 12. Discovery label-free mass
spectrometry was performed on controls (n = 10) and CRC (n = 16;
8 stage III/8 stage IV) patient plasma samples fractionated using
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(n=8) and CRC (n=16; 8 stage III/8 stage IV) patient plasma samples.
3.2. Proteomic profiling
Prior to label-free MS analysis, plasma samples were enriched using
ProteoMiner™ technology. ProteoMiner™ protein enrichment repre-
sents an effective and novel sample preparation method that can
concentrate low-abundance proteins and reduce the dynamic range of
protein concentrations in a sample using combinatorial hexapeptide li-
gand libraries (CPLL) [17,18]. CPLL are synthesised on beads by the split-
couple-recombine method using the 20 naturally occurring amino
acids, theoretically resulting in 64million different ligands, with each li-
gand fixed to a single bead. Specific binding of proteins to the CPLL is
thought to depend on the physicochemical properties of the protein
(e.g. conformation, hydrophobicity, and pI). High abundant proteins,
such as albumin and haptoglobin, will quickly saturate their ligand
quickly, whereas low abundant proteins will not saturate their binding
sites and consequently can be quantitatively analysedwhen eluted from
the matrix.
ProteoMiner™ fractionated samples were analysed by label-free MS
analysis, an established powerful method for peptide/protein Quantita-
tion. Progenesis LC–MS software was used to compare healthy controls
to stage III/IV CRC patient samples (Table 1). We included proteins that
were only identified by a single peptide (the so-called “one-hit” won-
ders) as the complexity of the plasma sample even after fractionation
was very high and resulted in much single hit identification (Table 2).
Of particular interest from the protein list was the number of 14-3-3
family members identified, 14-3-3 protein theta (θ/τ), 14-3-3 protein
gamma (γ), 14-3-3 protein epsilon (ε), 14-3-3 protein zeta/delta (ζ/δ)
and 14-3-3 protein beta/alpha (β/α), which were all found to be in-
creased in the stage III/IV CRC patient plasma samples (2.52-fold, 2.14-Table 2
Protein table.
Accession Platform Protein name Peptide
count
P08567 LC/MS Pleckstrin 1
P14618 LC/MS Pyruvate kinase isozymes M1/M2 1
P27348 LC/MS 14-3-3 protein theta 2
P60709 LC/MS Actin, cytoplasmic 1 8
P61981 LC/MS 14-3-3 protein gamma 1
P02774 LC/MS Vitamin D-binding protein 6
P68032 LC/MS Actin, alpha cardiac muscle 1 3
P62158 LC/MS Calmodulin 2
P10720 LC/MS Platelet factor 4 variant 2
Q562R1 LC/MS Beta-actin-like protein 2 1
P06733 LC/MS Alpha-enolase 6
P62258 LC/MS 14-3-3 protein epsilon 1
P06702 LC/MS Protein S100-A9 2
P63104 LC/MS 14-3-3 protein zeta/delta 3
P67936 LC/MS Tropomyosin alpha-4 chain 1
Q9Y490 LC/MS Talin-1 5
P04406 LC/MS Glyceraldehyde-3-phosphate dehydrogenase 3
P01009 LC/MS Alpha-1-antitrypsin 1
P31946 LC/MS 14-3-3 protein beta/alpha 1
P07437 LC/MS Tubulin beta chain 1
P04350 LC/MS Tubulin beta-4A chain 1
Q86UX7 LC/MS Fermitin family homolog 3 1
P0DJI8 LC/MS Serum amyloid A-1 protein 2
P09104 LC/MS Gamma-enolase 1
P23528 LC/MS Cofilin-1 1
P07996 LC/MS Thrombospondin-1 7
P28676 LC/MS Grancalcin 2
O43707 LC/MS Alpha-actinin-4 3
Q08043 LC/MS Alpha-actinin-3 1
List of proteins found to show statistically significant differences between control (n= 10) and
beads. Information provided in the table includes accession number, discovery platform used, p
tein identification (confidence number), ANOVA p-values (≥0.05), fold change in protein abunfold, 2.17-fold, 3.31-fold and 3.78-fold, respectively) compared to the
control group. The 14-3-3 family of proteins are not present in high con-
centrations, especially in the circulation, but their overexpression and
probably the ProteoMiner™ enrichment facilitated their identification
and quantitation in this study. Both pyruvate kinase isozymes M1/M2
(6.62-fold, p = 0.0003) and gamma enolase (4.50-fold, p = 0.02)
were found to be increased in CRC patient plasma samples respectively.
3.3. Metabolomic profiling
Of the molecules that were analysed by UHPLC–MS/MS in the nega-
tive and positive ion mode, mode and GC–MS, a number of these
analytes were found at statistically significant altered levels when com-
paring healthy controls to stage III/IV CRC patient plasma samples
(Table 3). Serotonin (5-HT) was discovered to be 3.11-fold increased
in CRC patient samples (p = 0.001). Two long chain fatty acid, Stearate
(18:0) (1.20-fold, p = 0.037) and oleate (18:1n9) (1.69-fold, p =
0.002) were found to be higher in healthy control plasma compared
to CRC patients. The gamma-glutamylated amino acids, gamma-
glutamylvaline (2.27-fold, p b 0.001) and gamma-glutamylleucine
(1.89-fold, p b 0.001) were also found to be higher in healthy control
specimens.
3.4. ELISA analysis of M2-PK, gamma enolase, 14-3-3 (pan) and serotonin
ELISA analysis of M2-PK, gamma enolase, 14-3-3 (pan) and seroto-
nin in plasma samples was performed in control (n = 20), polyps
(n = 10), adenoma (n = 10), stage I/II CRC (n = 20) and stage III/IV
(n = 20) patients. Box-and-whisker plots were constructed from this
ELISA data showing the median and interquartile range (Fig. 1).
M2-PK, gamma enolase, 14-3-3 (pan) and serotonin were found to be










80 0.0003 4.11 CRC Control
47 0.0003 6.62 CRC Control
120 0.0008 2.52 CRC Control
495 0.002 3.36 CRC Control
63 0.002 2.14 CRC Control
314 0.002 2.92 CRC Control
165 0.003 3.35 CRC Control
153 0.003 2.90 CRC Control
87 0.003 3.01 CRC Control
75 0.005 3.09 CRC Control
383 0.006 5.13 CRC Control
71 0.007 2.17 CRC Control
149 0.007 9.03 CRC Control
230 0.010 3.31 CRC Control
90 0.01 5.85 CRC Control
290 0.01 2.96 CRC Control
236 0.01 6.88 CRC Control
55 0.01 2.01 CRC Control
76 0.01 3.78 CRC Control
49 0.02 2.23 CRC Control
49 0.02 2.23 CRC Control
64 0.02 2.73 CRC Control
101 0.02 2.07 CRC Control
60 0.02 4.50 CRC Control
41 0.02 4.18 CRC Control
451 0.03 2.14 CRC Control
132 0.03 2.61 CRC Control
138 0.04 3.02 CRC Control
45 0.05 3.40 CRC Control
CRC (n=16; 8 stage III/8 stage IV) patient plasma samples fractionated using Proteominer
rotein description, the number of unique peptides for quantitation, a mascot score for pro-
dance (≥2-fold) and highest/lowest mean change.
Table 3
Metabolite table.
HMDB Platform Biochemical name ANOVA (p) Fold change Highest mean condition Lowest mean condition
HMDB06344 LC/MS pos phenylacetylglutamine 0.005 2.88 CRC Control
HMDB00259 LC/MS pos serotonin (5HT) 0.001 3.11 CRC Control
HMDB00682 LC/MS neg 3-indoxyl sulfate 0.028 2.03 CRC Control
HMDB02302 LC/MS neg indolepropionate 0.002 4.26 CRC Control
HMDB11172 LC/MS pos gamma-glutamylvaline b0.001 2.27 Control CRC
HMDB11171 LC/MS pos gamma-glutamylleucine b0.001 1.89 Control CRC
HMDB00827 LC/MS neg stearate (18:0) 0.037 1.20 Control CRC
HMDB00207 GC/MS oleate (18:1n9) 0.002 1.69 Control CRC
HMDB00848 LC/MS pos stearoylcarnitine 0.004 1.45 Control CRC
HMDB05065 LC/MS pos oleoylcarnitine b0.001 1.75 Control CRC
HMDB00660 GC/MS fructose 0.010 2.12 CRC Control
HMDB00209 LC/MS neg phenylacetate 0.018 1.68 CRC Control
List of metabolites found to show statistically significant differences between control (n= 8) and CRC (n= 16; 8 stage III/8 stage IV) patient plasma samples. Included in the table is the
Human Metabolome Database (HMDB) entry, platform used to analyse the biochemicals, biochemical name, ANOVA p-values (≥0.05), fold-change and highest/lowest mean change.
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stage III/IV, p= 0.01), gamma enolase (control vs. stage I/II, p b 0.0001;
control vs. stage III/IV, p= 0.002; polyps vs. stage III/IV, p=0.0003; ad-
enoma vs. stage III/IV, p = 0.0001; stage I/II vs. stage III/IV, p b 0.0001),
14-3-3 (pan) (control vs. adenoma, p= 0.04; stage I/II vs. stage III/IV
p b 0.0001) and serotonin (control vs. stage III/IV, p b 0.0001; polyps
vs. stage III/IV, p = 0.0003; adenoma vs. stage III/IV, p = 0.0002;
stage I/II vs. stage III/IV, p = 0.003).
The most significant AUC-values for Control vs. Stage I/II was 0.82
(14-3-3 (pan)), Control vs. Stage III/IV 0.89 (Gamma Enolase), Polyps
vs. Stage I/II 0.78 (M2-PK), Polyps vs. Stage III/IV 0.91 (Serotonin), Ade-
nomavs. Stage I/II 0.70 (14-3-3 (pan)) andAdenoma vs. Stage III/IV 0.93
(Serotonin). These results indicate that all four candidate biomarkers
investigated post discovery phase have significant discriminatory
power when comparing control, polyps or adenoma to stage I/II and
stage III/IV CRC patient samples (Table 4).Fig. 1. Box andwhisker plots for (A)M2-PK, (B) gamma enolase, (C) 14-3-3 (pan) and (D) serot
ples from control (n = 20), polyps (n = 10), adenoma (n = 10), stage I/II CRC (n = 20) and s
comparisons between the different sample groups. This ELISA measurement for 14-3-3 detects3.5. Immunohistochemistry
14-3-3 ε was selected for further analysis as this protein was found
to be statistically significant from the proteomics profiling of plasma
samples from control and CRC patients (p = 0.0008). A tissue
microarray comprising of 24 cores of colon cancer tissues with corre-
sponding normal tissues was stained for 14-3-3 ε expression using an
anti-14-3-3 ε polyclonal antibody. A representative immunohistochem-
ical analysis of 14-3-3 ε is shown in Fig. 2. Each corewas appraised using
basic annotation parameters for evaluation of staining intensity (nega-
tive, weak, moderate or strong). Results indicated a higher level of ex-
pression for 14-3-3 ε in malignant compared to non-malignant tissue
based on the following counts: for malignant: negative (0/12, 0%),
weak (0/12, 0%), moderate (5/12, 42%) or strong (7/12, 58%) and
adjacent normal: negative (0/12, 0%), weak (5/12, 42%), moderate
(6/12, 50%) or strong (1/12, 8%).onin. ELISA analysis ofM2-PK, gamma enolase, serotonin and 14-3-3 (pan) in plasma sam-
tage III/IV (n = 20) patients. The figures show statistically significant p-value for various
all known isoforms of mammalian 14-3-3 proteins (β/α, γ, ε, η, ζ/δ, θ/τ and σ).
Table 4
AUC (area under curve) values.
M2-PK Gamma enolase 14-3-3 (pan) Serotonin
Control vs. Stage I/II 0.60 0.55 0.82 0.57
Control vs. Stage III/IV 0.68 0.89 0.67 0.88
Polyps vs. Stage I/II 0.78 0.53 0.65 0.55
Polyps vs. Stage III/IV 0.78 0.89 0.53 0.91
Adenoma vs. Stage I/II 0.56 0.55 0.70 0.65
Adenoma vs. Stage III/IV 0.58 0.92 0.57 0.93
AUC (area under curve) values associatedwith comparisons of control, polyps and adeno-
ma to both stage I/II and stage III/IV CRC for M2-PK, gamma enolase, 14-3-3 (pan) and
serotonin.
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Circulating levels of disease-related biomolecules have the potential
to be used for a number of important applications in themanagement of
cancer patients includingmore precise diagnosis, stratification, progno-
sis, surveillance andmonitoring response to treatment. Blood basedbio-
markers may also give insight into tumour biology, with many of the
biomolecules secreted or shed from tumour cells or surrounding cells
in the microenvironment providing important information into the
pathogenic mechanisms. Carcinoembryonic antigen (CEA) used for sur-
veillance of patients following primary surgical resection and carbohy-
drate antigen 19-9 (CA19-9) as a prognostic indicator are the most
widely used serum biomarkers in CRC [19–21].
More accurate biomarkers are needed that reflect CRC tumour biol-
ogy for early detection andmonitoring treatment response as new ther-
apeutic strategies emerge. Conventional colonoscopy (CC) is considered
the “gold standard” by whichwemeasure any other CRC screening test,
but with low patient acceptance rates andwaiting lists for colonoscopy,
this technique cannot be considered a realistic method for serialFig. 2. Immunohistochemistry. Representative immunohistochemical analysis of 14-3-3 ε using
B. Adenocarcinoma of the colon (Grade: 2, Stage: II, TNM:T3N1M0). C. Normal adjacent colon ti
significantly higher in the adenocarcinoma of the colon as compared with that of the normal amonitoring. Ideally, a set of measurable blood-based companion bio-
markers, reflecting tumour development and burden, together with
the advantage of being cost-effective, routine to perform and with
short analysis times would be beneficial to conduct in parallel.
The analysis performed in this report identifies a link between
higher expression levels reported in the literature in CRC tissue speci-
mens and in this study, with increased circulatory levels of 14-3-3 pro-
teins. 14-3-3 proteins are established intracellular proteins, mainly
found in the cytosol, nucleus or associated with the plasma membrane.
Tumour cells secret or shed a larger selection of important molecules,
such as hormones, growth factors, and cytokines through well
characterised mechanisms. However, many intracellular proteins are
likely to be released into the extracellular environment due to vesicula-
tion, cell lysis, apoptosis, and necrosis [22,23]. The ELISA used in this in-
vestigation was a pan 14-3-3 assay, evaluating all family members in a
single measurement. Given the conflicting reports on the over- and
under-expression levels for specific familymembers (e.g. 14-3-3σ), ide-
ally this analysiswould beperformedusing specific ELISAs to each of the
family members individually [24,25]. It is very likely that some of the
family members will play important roles in tumour biology at various
stages during progression, from early development to establishingmet-
astatic colonies. Tissue levels for 14-3-3 ε were also examined as this
protein was amongst the most statistically significant. Overall, the
data indicate increased staining levels in CRC tissue compared to sur-
rounding control tissue, as other groups have reported [26].
14-3-3 proteins are highly conserved and ubiquitously expressed
with seven isoforms, beta/alpha (β/α), gamma (γ), epsilon (ε),
eta (η), zeta/delta (ζ/δ), theta/tau (θ/τ) and sigma (σ) identified in
mammals. Through their amino-terminal α helical region, 14-3-3 pro-
teins form homo- or heterodimers that interact with a wide variety of
signalling proteins including transcription factors (forkhead box O),
metabolic enzymes, kinases (c-Raf Ser/Thr kinase), phosphatases
(cdc25 tyrosine phosphatases) and cytoskeletal proteins [27–29].a tissuemicroarray in A. Adenocarcinoma of the colon (Grade: 2, Stage: II, TNM:T3N1M0).
ssue (for A). D. Normal adjacent colon tissue (for B). The staining intensity of 14-3-3 εwas
djacent tissue. The bar on each image represents 200 μm.
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close relationship between 14-3-3 proteins and many types of cancer
[30–32]. Most of these investigations are based on measuring levels of
individual members of the 14-3-3 family by immunohistochemistry in
cell lines or clinical tissue biopsies and correlating their expression
valueswith clinical outcome and their role in regulating signalling path-
ways in tumour cells [33,34].
With a focus on CRC, Wang and co-workers reported on the investi-
gation of 14-3-3 ε expression and its prognostic significance in CRC
using immunohistochemical analysis of 137 clinicopathologically
characterised cases. The data points to poor overall survival in CRC pa-
tients correlating with a loss of nuclear 14-3-3 ε expression levels
[35]. Of the seven family members for 14-3-3 proteins, Sakai et al., re-
ported that 14-3-3 β, γ, and σ proteins were found to be up-regulated
in a 5-fluorouracil (5-FU) resistant cell line model (DLD-1/5-FU cells)
compared to the parental cell line [36]. These results suggest an impor-
tant role for these three proteins as antiapoptotic regulators and con-
veyers of drug resistance.
Few reports exist with reference to circulating levels of specific 14-3-3
protein family members in relation to specific disease states. Numerous
investigations have positively correlated increasing levels of 14-3-3 pro-
teins with the diagnosis of Creutzfeldt-Jakob disease in cerebrospinal
fluid (CSF) [37–40]. Hatzipetros and co-workers investigated the levels
based on previous findings [41,42], but concluded that levels of 14-3-3 ζ
protein were not found to reliably correlate with the clinical behaviour
of epithelial ovarian cancer [43]. An enzyme-linked immunosorbent
assay (ELISA) was recently developed to detect the 14-3-3 η protein and
aid as a newdiagnostic tool for the early identification of inflammatory ar-
thritis specifically in synovial fluid [44], and urinary 14-3-3 β/α protein
has been reported as a candidate biomarker for renal cell carcinoma [45].
Results considered in this study suggest a correlation with increased
levels of serotonin and the development of pre-malignant and malig-
nant stages of CRC, perhaps relating to the synthesis or storage by the
enterochromaffin cells. Considering reports on serotonin's role in pro-
moting tumour growth and survival, a possible autocrine-like signalling
pathway could play a role in CRC tumourogenesis [46,47]. Serotonin is a
widely studied neurotransmitter/growth factor and was found to be
consistently statistically significant when comparing plasma levels in
individuals diagnosed with polyps compared to adenoma, stage I/II
and stage III/IV patients. The gastrointestinal (GI) tract is the largest pro-
ducer of serotonin (5-hydroxytryptamine (5-HT)) in the body, and as
such it is intimately connectedwithGI function andphysiology. Thema-
jority of serotonin in the body, approximately 90%, is synthesised by the
enterochromaffin cells of the gastrointestinal tract. Over 60 years ago,
Lembeck reported increased plasma 5HT in a patient with carcinoid tu-
mour [48]. Since then, other groups have also reported onmeasurement
of serotonin in cancer patient blood samples [49].
Coogan et al. found an association of reduced risk of CRCwith regular
use of selective serotonin reuptake inhibitors (SSRIs) [50], however
other groups have found no link with antidepressant use [51]. Overex-
pression of serotonin receptors have also been implicated in the devel-
opment of tumours through analysis of colon cancer tissue and the
HT29 (human colon adenocarcinoma) cell line [47]. In breast cancer,
correlation analysis revealed a significant link between the serotonin re-
ceptor, 5-Hydroxytryptamine receptor 2B (5-HTR2B) and estrogen
receptor-α (ER-α) as well as between another serotonin receptor,
5-hydroxytryptamine receptor 4 (5-HTR4) and ER-α/progesterone re-
ceptor (PR) [52].
Of the other metabolites, phenylacetylglutamine levels are associat-
edwith tumour cytostasis and differentiation [53], with abnormal levels
of stearoylcarnitine and oleoylcarnitine involved in lipid metabolism,
frequently found to be deregulated in cancer cells [54]. Fructose is asso-
ciatedwithmore aggressive cancer behaviour andmay promotemetas-
tasis, with a recent publication revealing higher-than-normal blood
levels of fructose in pancreatic cancer patients, a trend that was found
in this investigation [55,56].Two proteins that were investigated in more detail after discovery
proteomics and metabolomics were gamma enolase and PKM2 (pyru-
vate kinase isozymes M1/M2 in the protein list). Both of these proteins
were found to show statistically significant fold-changes and demon-
strated very similar expression level profiles in the plasma proteome
comparing non-malignant andmalignant patient samples. Gammaeno-
lase, also known as enolase 2 (ENO2) or neuron-specific enolase, is an
enzyme that in humans is encoded by the ENO2 gene and is the neuro-
nal isoform of the glycolytic enzyme enolase that is involved in glucose
metabolism [57]. This dimeric enzyme is mainly expressed in neurons
(γγ-enolase) and in neuroendocrine cells (αγ-enolase) and is found
in CSF, correlating with brain injury after cardiopulmonary arrest [58].
Gamma enolase has been reported as upregulated in a number of can-
cers, including participating in the tumourogenesis of CRC [59–64].
Many reports in the literature have firmly established a link between
PKM2 expression levels and various cancers, by IHC, biofluid and MS
based analyses [65–67]. The synergy with CRC is also well documented
[68–70], including elevated levels detected in patient faecal specimens
[71,72]. Pyruvate kinase catalyzes the last step in the process of glycol-
ysis (rate-limiting), transfer of a high-energy phosphate group from
phosphoenolpyruvate (PEP) to ADP, producing ATP and pyruvate. Can-
cer cells predominantly express PKM2 (regulated by oncogenes and tu-
mour suppressors), the basis for the tumour M2-PK test, which was
used as part of this investigation [73,74].
Altered metabolism is a characteristic of most cancer cells, revolving
around central themes especially ATP generation and biosynthesis of
macromolecules [75,76]. Metabolic enzymes are a key component of
these metabolic changes, including gamma enolase and PKM2, both
found to be significantly increased in plasma samples from CRC patients
compared to control groups. There is also increasing evidence for the
role of fructose in cancer cellmetabolism, amolecule found to be elevat-
ed in this study from CRC samples compared to healthy controls. Liu
et al. presented data showing the contribution of fructose to nucleic
acid synthesis in cancer cells via TKT-mediated metabolism to facilitate
increased proliferative capacity [77].
5. Conclusion
In conclusion, proteomic and metabolomic analysis of plasma pa-
tient samples is a powerful strategy to discover candidate protein bio-
markers for CRC. These biomarkers have the potential to be used for
the development of blood-based tests to support clinical management
of CRC in combination with established blood-based biomarkers and
colonoscopy screening. The data presented in this investigation may
warrant future analysis of a large number of clinical samples with in-
depth patient information in order to establish an evidence-based as-
sessment of clinical utility.
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